C. Michael Gibson MD· @CMichaelGibson · X·· 11 小时前评分70
正文 · 机器翻译
在 HER2 阳性晚期 #breastcancer 患者中，HER2 靶向双特异性抗体 #anbenitamab 联合白蛋白结合型多西他赛使 24 个月无进展生存率达到 58.5%，而标准治疗组为 34.4%。
#ESMO26
https://nej.md/4BcWlF3
212 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org来源：C. Michael Gibson MD · x.com